#United States #cancer therapy #Intensity Therapeutics #Shelton #INTS

Intensity Therapeutics Implements Reverse Stock Split

Summary

Intensity Therapeutics, Inc., a biotechnology company dedicated to developing innovative cancer therapies, has announced a strategic move to conduct a reverse stock split. This decision is anticipated to aid in enhancing the company's trading share price on the Nasdaq Capital Market, with the rollout set for February 19, 2026.

Details of the Reverse Stock Split

The company approved a 1-for-25 reverse stock split, meaning that for every twenty-five current shares held by investors, they will receive one new share. This adjustment is expected to elevate the per-share trading price, thereby helping Intensity Therapeutics to meet the minimum bid price requirement for ongoing listing on the Nasdaq Exchange.

This reverse split was endorsed by the company’s stockholders during a special meeting held on October 22, 2025. It will take legal effect on February 18, 2026, at precisely 4:01 PM EST. Following this, shares will be re-traded under a new CUSIP number:

• - New CUSIP: 45828J 202
• - Ticker Symbol: INTS

Implications for Shareholders

The reverse stock split will reduce the overall number of shares in circulation from about 63 million down to approximately 2.5 million. Fractional shares will not be created; instead, shareholders with a resulting fractional share will receive cash payments based on the previous day's closing sale price for their shares.

Shareholders who maintain their investments electronically will not need to do anything to receive their post-split shares. Those with physical stock certificates will receive instructions from Continental Stock Transfer Trust regarding how to exchange their shares for the new listing.

About INT230-6

Central to Intensity’s therapeutic developments is its leading investigational candidate, INT230-6. This innovative treatment is designed for direct intratumoral injection and utilizes the company's proprietary DfuseRx technology platform. The medication combines two well-known anti-cancer agents—cisplatin and vinblastine sulfate—with an enhancing molecule to ensure deep penetration within tumors.

INT230-6 shows a compelling safety profile and prompts an effective immune response, even for tumors that do not typically react to standard immunotherapies. It has undergone extensive clinical trials, detailing its effectiveness in causing tumor regression as well as fostering adaptive immune responses post-administration.

Future Trajectory

As Intensity Therapeutics continues to progress through its clinical trials, including pivotal studies in metastatic and locally advanced cancers, the reverse stock split is designed to reestablish investor confidence and improve share viability. The firm has completed multiple trials, including the INVINCIBLE-2 study and the more recent INVINCIBLE-3 trial, showcasing its commitment to improving patient outcomes through innovative science.

Conclusion

Overall, the reverse split is not just a financial strategy; it underscores Intensity's focus on gaining compliance with regulatory requirements while pushing forward in the competitive biotechnology landscape. The management's aim is clear: refine the company's market positioning while propelling its groundbreaking cancer treatments to the forefront of therapeutic options for patients worldwide. For further updates on their progress within the biotechnology sector, stakeholders are encouraged to visit the company’s official website.

For any inquiries or more detailed information, please refer to the company's investor relations contact, Justin Kulik.

• ---

For the latest developments and additional information about Intensity Therapeutics, please visit www.intensitytherapeutics.com.